v3.26.3
EQUITY
 12 Months Ended
Jun. 30, 2026
EQUITY  
EQUITY

NOTE 10 – EQUITY

 

Common Stock

 

As of June 30, 2026, and 2025, the Company had 5,000,000,000 shares of common stock authorized with a par value of $0.00001. There were 1,059,924,580 and 695,746,625 shares issued and outstanding as of June 30, 2026 and 2025, respectively.

 

During the year ended June 30, 2026, the Company issued 26,700,855 shares of common stock in exchange for services, valued at $260,000.

 

Series A Preferred Stock

 

There are 100,000,000 shares authorized as preferred stock, of which 3,500,000 are designated as Series A preferred stock having a par value of $0.00001 per share. The Series A preferred stock has the following rights:

 

 

·

Voting: The preferred shares shall be entitled to 1,000 votes to every one share of common stock.

 

 

 

 

·

Dividends: The Series A preferred stockholders are treated the same as the common stockholders except at the dividend on each share of Series A convertible preferred stock is equal to the amount of the dividend declared and paid on each share of common stock multiplied by the Conversion Rate.

 

 

 

 

·

Conversion: Each share of Series A Preferred Stock is convertible, at the option of the holder thereof, at any time into shares of Common Stock on a 1:1,000 basis.

 

 

 

 

·

The shares of Series A Preferred Stock are redeemable at the option of the Corporation upon not less than 30 days written notice to the holders. It is not mandatorily redeemable.

 

During the year ended June 30, 2026, 117,404 shares of Series A Preferred Stock were converted into 117,404,000 shares of common stock.

 

As of June 30, 2026 and 2025, the Company had 547,592 and 664,996 shares of Series A preferred stock issued and outstanding, respectively.

 

Series B Preferred Stock

 

On March 25, 2021, the Certificate of Designation for the Series B Preferred was recorded by the State of Nevada. There are 100,000,000 shares authorized as preferred stock, of which 1,000,000 are designated as Series B Preferred Stock having a par value of $0.00001 per share. The Series B preferred stock is not convertible, grants 5,000 votes and no liquidation preference.

 

As of June 30, 2026 and 2025, the Company had 1,000,000 shares of Series B preferred stock issued and outstanding.

 

Warrants

 

As of June 30, 2026 and 2025, the Company had 210,318,828 and 126,568,828 warrants outstanding. The warrants have a term of two to five years, and an exercise price range from $0.01 and $0.1187. The Company evaluated the warrants under ASC 815, Derivatives and Hedging (“ASC 815”) and determined that they did not require liability classification. The warrants were recorded in additional paid-in capital under their aggregate relative fair values. As of June 30, 2026, the weighted average remaining useful life of the warrants was 1.54. The warrants are detailed as follows:

 

 

 

 

Number of

Warrants 

 

 

 

Weighted-

Average

Exercise

Price

 

 

Weighted-

Average

Contractual

Term

(in years)

 

 

 

Aggregate

 Intrinsic

Value

 

Outstanding at June 30, 2024

 

 

118,968,828

 

 

$0.09

 

 

 

2.50

 

 

$-

 

Granted

 

 

7,900,000

 

 

$0.01

 

 

 

3.00

 

 

$-

 

Exercised

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Canceled

 

 

(300,000)

 

 

 

 

 

 

 

 

 

 

 

 

Outstanding at June 30, 2025

 

 

126,568,828

 

 

$0.095

 

 

 

1.90

 

 

$-

 

Granted

 

 

83,750,000

 

 

$0.01

 

 

 

3.00

 

 

$-

 

Exercised

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Canceled

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

Total at June 30, 2026

 

 

210,318,828

 

 

$0.056

 

 

 

1.54

 

 

$-

 

Exercisable at June 30, 2026

 

 

210,318,828

 

 

$0.056

 

 

 

1.54

 

 

$-